Tetratherix (ASX:TTX) has announced a major clinical milestone for its TetraDerm product, with the completion of the second safety review of the trial’s second cohort.
All nine patients in this cohort completed their six-week follow-up assessments with no procedural or technical adverse events, reinforcing the safety profile of TetraDerm’s patented biomaterial polymer platform.
Principal investigator Dr Drew Cronin will begin patient enrolment for the third and final cohort in the first quarter of 2026, focusing primarily on patients undergoing body contouring procedures following significant weight loss—a fast-growing segment of the plastic and reconstructive surgery market.
The transition into this cohort marks the final validation stage of TetraDerm’s pre-commercialisation pathway and highlights its potential to reduce scarring, improve wound healing, and enhance patient quality of life following major surgeries.
CEO Will Knox described the development as a "high-margin, scalable solution to a multi-billion-dollar problem," emphasising that TetraDerm's clinical validation positions Tetratherix at the forefront of surgical site management.